about
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsXB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt.The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma.Cytosolic phospholipase A2 alpha regulates cell growth in RET/PTC-transformed thyroid cells.Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer.Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.BRAF is a therapeutic target in aggressive thyroid carcinoma.Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.
P50
Q24519206-1CF24EB9-9429-432B-A0AE-6625412B5920Q34296396-D1614360-E1D4-40F4-A3DE-A1D0C9112C54Q37351482-AF8DCBA0-6D54-4E21-A8C0-1FBCA499D10EQ37454049-998E932A-C63A-49BE-8222-C2BE300BA5F4Q38305935-2121F967-E3A8-4B0B-A94C-9AA02F5ED144Q39644790-1379C9B5-1620-49F6-AEEC-CE8DA7B8DACBQ39647581-BA580234-49D4-441A-BEDA-05EA2997E356Q39776625-82D3D42B-EEA6-47D2-8F20-A159BC6B5D32Q39951413-C0A75931-E00C-4688-B9EE-B149BD2727ECQ40033622-CAEDC05E-3A5C-493F-977C-20962396294BQ40311453-00E4A68F-5222-41B1-B706-8454E4D16600Q42807760-0C9DC11E-334C-4D71-80BB-E5592E9B5F3DQ43251079-C2013A71-A44C-4F59-A3E6-D4C6EC5A2B3DQ44278362-BA17C992-2311-4D08-85BD-E08DA25A8C05Q45096548-634D48EF-1939-4730-A6C0-0C5E40B9DFBCQ46211426-D07D80D9-D702-4F6A-A0DE-50949AB4F427Q46988427-B9A36895-351E-46AF-A410-3D5BF1D21EF8Q54367200-29892B0D-77AE-4569-B648-D3C6F257B48EQ54655522-C10215C8-5523-4DC1-B0B4-C66C56368BE3
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-8972-7921
@en
name
Valentina De Falco
@ast
Valentina De Falco
@en
Valentina De Falco
@nl
type
label
Valentina De Falco
@ast
Valentina De Falco
@en
Valentina De Falco
@nl
prefLabel
Valentina De Falco
@ast
Valentina De Falco
@en
Valentina De Falco
@nl
P106
P31
P496
0000-0002-8972-7921